Literature DB >> 3864639

Stimulation of HLA-A,B,C by IFN-alpha. The derivation of Molt 4 variants and the differential expression of HLA-A,B,C subsets.

O R Burrone, R F Kefford, D Gilmore, C Milstein.   

Abstract

Spontaneous mutants with altered HLA-A,B,C response to interferon-alpha (IFN-alpha) were isolated from the human thymus leukemia cell line Molt 4. Using fluorescein isothiocyanate (FITC)-conjugated W6/32 (a monoclonal antibody to HLA-A,B,C) and the fluorescence-activated cell sorter, the cells with highest and lowest fluorescence after 24-48 h of IFN-alpha treatment were selected and expanded. After several cycles of selection, mutant clones with low (greater than 10% of wild-type) and high (three times better) response were obtained. A similar protocol was employed to derive high responder mutants with the monoclonal antibody YT76, which recognises a subset of HLA strongly induced by IFN-alpha. Stable clones were derived for which YT-HLA induction was 7-fold that of Molt 4 cells and for which HLA induction occurred at 100-fold lower concentrations of IFN-alpha. The high response phenotype of the mutants was not accompanied by a significant increase in the constitutive level of expression of HLA-A,B,C (in the absence of IFN). The increase in the level of HLA-A,B,C expression after IFN-alpha treatment is mostly accounted for by the increase in the expression of a subset of HLA molecules, detected by the monoclonal antibody YT76 including HLA-B molecules.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3864639      PMCID: PMC554589          DOI: 10.1002/j.1460-2075.1985.tb04014.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  27 in total

1.  Chromosome 21 and the cell growth inhibitory effect of human interferon preparations.

Authors:  Y H Tan
Journal:  Nature       Date:  1976-03-11       Impact factor: 49.962

Review 2.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  A monoclonal antibody for large-scale purification of human leukocyte interferon.

Authors:  D S Secher; D C Burke
Journal:  Nature       Date:  1980-06-12       Impact factor: 49.962

Review 4.  Cytolytic T lymphocytes.

Authors:  M Nabholz; H R MacDonald
Journal:  Annu Rev Immunol       Date:  1983       Impact factor: 28.527

5.  High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor.

Authors:  M Aguet
Journal:  Nature       Date:  1980-04-03       Impact factor: 49.962

6.  Enhanced expression of HLA antigens and beta 2-microglobulin on interferon-treated human lymphoid cells.

Authors:  M Fellous; M Kamoun; I Gresser; R Bono
Journal:  Eur J Immunol       Date:  1979-06       Impact factor: 5.532

7.  A human thymocyte antigen defined by a hybrid myeloma monoclonal antibody.

Authors:  A J McMichael; J R Pilch; G Galfré; D Y Mason; J W Fabre; C Milstein
Journal:  Eur J Immunol       Date:  1979-03       Impact factor: 5.532

8.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

9.  Subregional localization of the gene(s) governing the human interferon induced antiviral state in man.

Authors:  Y H Tan; A E Greene
Journal:  J Gen Virol       Date:  1976-07       Impact factor: 3.891

10.  Somatic variants of the level of expression of a cell surface antigen.

Authors:  O R Burrone; F Calabi; R F Kefford; C Milstein
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  9 in total

1.  Differential regulation of HLA class I genes by interferon.

Authors:  H Schmidt; V Gekeler; H Haas; G Engler-Blum; I Steiert; H Probst; C A Müller
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

2.  An HLA-B regulatory element binds a factor immunologically related to the upstream stimulation factor.

Authors:  J Girdlestone
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

3.  Transcriptional regulation of HLA-A and -B: differential binding of members of the Rel and IRF families of transcription factors.

Authors:  J Girdlestone; M Isamat; D Gewert; C Milstein
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

4.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846

5.  In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN alpha treatment.

Authors:  C A Müller; J Walz; R Zinser; H J Bühring; B Steinke; H Schmidt
Journal:  Ann Hematol       Date:  1991-11       Impact factor: 3.673

6.  Phorbol esters potentiate the induction of class I HLA expression by interferon alpha.

Authors:  J D Erusalimsky; R F Kefford; D J Gilmore; C Milstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

7.  Unmasking the suppressed immunopeptidome of EZH2-mutated diffuse large B-cell lymphomas through combination drug treatment.

Authors:  Christopher M Bourne; Sung Soo Mun; Tao Dao; Zita E H Aretz; Zaki Molvi; Ron S Gejman; Andrew Daman; Katsuyoshi Takata; Christian Steidl; Martin G Klatt; David A Scheinberg
Journal:  Blood Adv       Date:  2022-07-26

8.  HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas.

Authors:  M A López-Nevot; F Esteban; A Ferrón; J Gutiérrez; M R Oliva; C Romero; C Huelin; F Ruiz-Cabello; F Garrido
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

9.  An Integrated Genomic, Proteomic, and Immunopeptidomic Approach to Discover Treatment-Induced Neoantigens.

Authors:  Niclas Olsson; Marlene L Heberling; Lichao Zhang; Suchit Jhunjhunwala; Qui T Phung; Sarah Lin; Veronica G Anania; Jennie R Lill; Joshua E Elias
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.